Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa study of SGN1 in advanced solid tumors
ChiCTR2400079374Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SGN1 in Nonhematologic neoplasms, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC) and 14 more, sponsored by West China Hospital of Sichuan University. Primary endpoints: objective response rate, disease control rate and 1 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
SGN1
03
Conditions
Nonhematologic neoplasmshepatocellular carcinoma (HCC)small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2400079374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079374.